Affibody Medical AB

Affibody is strategically focused on advancing our pipeline of radioligand therapeutics that offer a competitive advantage and significant opportunities to benefit cancer patients. Our pipeline also includes partnership programs in immunology.

Anyone who was a shareholder in Affibody Medical AB on the record date of January 23, 2026 has preferential rights to subscribe for shares, in relation to previous shareholdings. Anyone who is a registered shareholder on the record date shall recieve four (4) subscription rights for each held share in Affibody Medical AB. To subscribe for one (1) new share at the subscription price of 22 SEK per share, seven (7) subscription rights are needed. For subscription without subscription rights, the above registration form can be used. When subscribing via ISK/KF accounts, subscription must be made in agreement with the bank/custodian where the account is located.